The urine lipoarabinomannan assay (Determine TB-LAM; Alere, MA, USA) was conditionally endorsed by WHO in 2015 for use in adults with HIV who are admitted to hospital with signs and symptoms of tuberculosis, and have a CD4 count less than 100 cells per µL or are seriously ill. 5 In 2016, a randomised controlled trial 6 showed that the use of urine LAM could reduce mortality in symptomatic patients with HIV and low CD4 cell counts admitted to hospital. However, despite the WHO policy and the trial results, uptake of urine LAM has been poor, 7 perhaps due to challenges in interpreting the current conditional policy and the fact that national tuberculosis programmes are usually not engaged in managing severely ill patients who are admitted to hospital.
The STAMP trial, reported in The Lancet, by Ankur Gupta-Wright and colleagues 8 randomly assigned 2600 HIV-positive patients to the standardof-care screening group (sputum Xpert MTB/RIF [Xpert], Cepheid, CA, USA) and intervention screening group (sputum and urine Xpert plus urine LAM) in Malawi and South Africa. The primary endpoint was all-cause 56-day mortality, and was not significantly different between the two groups (absolute adjusted risk reduction -2·8%, 95% CI -5·8 to 0·3; p=0·074. However, Gupta-Wright and colleagues' trial showed that in three of 12 prespecified patient subgroups, which were underpowered, a significant mortality reduction was observed between the intervention group and standard-of-care group: adjusted risk reduction was -7·1% (95% CI -13·7 to -0·4) in patients with CD4 counts less than 100 cells per µL, -9·0% (-16·6 to -1·3) in those with haemoglobin less than 8 g/dL, and -5·7% (-10·9 to -0·5) in those with clinically suspected tuberculosis at admission.
Their study 8 also showed a significant increase in the number of patients diagnosed with and treated for tuberculosis between the intervention group and the standard-of-care group. Although mortality reduction is a welcome outcome for a study of diagnostic test effectiveness, it should not be the only person-centred outcome that is prioritised. Successful completion of the entire care cascade is what saves lives. 9 Transmission from unsuspected tuberculosis is a major driver of the ongoing epidemic and therefore earlier diagnosis, followed by linkage and retention in care, is an important component of tuberculosis elimination efforts.
Although forthcoming cost-effectiveness data from the STAMP trial and additional studies will help to inform updated WHO recommendations on LAM, the re-emergence of tuberculosis as the leading cause of infectious disease-related adult deaths is a reminder that the cost of not adopting more ambitious strategies to manage tuberculosis is too high. LAM is inexpensive and can be easily done in the majority of patients with HIV (99% in the STAMP trial), in contrast to sputum Xpert (57% in the STAMP trial). Therefore, even if the mortality reduction is modest (less than 5%), using LAM as a screening test for HIV-infected patients in hospitals with high tuberculosis and HIV co-prevalence might increase the yield of tuberculosis diagnosis, as well as reduce tuberculosis-related mortality. Of note, patients who were unable to consent because of critical illness were excluded, which might have biased the study towards the null since this group might have been more likely to benefit from rapid tuberculosis diagnosis using the LAM assay.
The STAMP trial further emphasises the need for a non-sputum based, rapid, point-of-care tuberculosis diagnostic test. To have a bigger impact, additional work is needed to improve the sensitivity of urine LAM testing in HIV-negative patients, and there is proof of concept that this improvement can be done. 10 In a study by Paris and colleagues, 11 nanocage technology and a copper-complex reactive dye were used to evaluate the concentration of lipoarabinomannan in the pretreatment urine of 48 HIV-negative patients with microbiologically confirmed active pulmonary tuberculosis from a Peruvian hospital. Compared with age-matched healthy volunteers and those with non-tuberculosis diseases, Paris and colleagues reported a sensitivity of 96% and specificity of 81%. This finding is a promising step towards wider use of urine LAM, but substantial product development will be required to move this technology toward a standardised point-ofcare test, along with larger field studies. Other product developers are also engaged in improving urine LAM testing, but published data are scarce. 10 With the upcoming UN High Level Meeting on Tuberculosis, the tuberculosis community has prioritised among their Key Asks (ie, priority actions), affordable point-of-care tuberculosis diagnostics that can identify new infections and tests for drug resistance by 2025. 12 While the tuberculosis community waits for such new tools, they must scale up the best tools they already have. This action is the surest way to spur development and facilitate implementation of novel technologies in the pipeline. Failure to do so endangers patients and communities.
